Clinical Decision Support for Unsolicited Genomic Results
主动提供的基因组结果的临床决策支持
基本信息
- 批准号:10672256
- 负责人:
- 金额:$ 48.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAdoptedAdoptionAreaAwardClinicalCommittee MembersDataDiagnosisDiseaseFeedbackFocus GroupsFutureGenomic medicineGenomicsGoalsHealthHealth PersonnelHealth systemHealthcareIndividualInfrastructureInstitutionInstitutional PolicyLearningModelingMotionNational Human Genome Research InstituteOutcomePatientsPersonsPreventionProcessRecommendationResearchResearch MethodologyRiskRoleScienceStructureSurveysSystemTest ResultTestingTherapeutics CommitteeTimeTime and Motion StudiesVisionWorkadverse drug reactionclinical careclinical decision supportcomputerized toolsdashboarddesignempowermentevidence basegenetic makeupgenomic datahealth care settingsimplementation scienceimprovedinterestmeetingspreferenceprogramsprovider adoptionresearch studysocialusability
项目摘要
Project Summary
As healthy individuals increasingly can receive genomic testing results that indicate their risk for poor
outcomes (e.g. diseases or adverse drug reactions), healthcare providers will need to ensure that the results
are handled prudently, by addressing the receipt of the results, the workflow challenges, and liability issues.
Given that clinical genomic tests can be initiated outside of the clinical setting (e.g., in a research study), from
the clinician’s perspective, they can be characterized as unsolicited genomic results (UGR). Clinical decision
support (CDS) has great potential to ease the adoption of UGR by providing clinicians with recommendations
and patient-related information presented at particular times to enhance clinical care. Deploying CDS for UGR
in a healthcare setting in a scalable way, however, will depend on our capacity to leverage local institutional
policy and oversight structures to approve of CDS guidance and strategies for UGR. The specific objective of
this research program is to develop and evaluate the Evidence-based Decision support Implementation
over Time (EDIT) model for prioritizing and revising deployed CDS for UGR. The EDIT model will empower
local oversight committees such as Pharmacy & Therapeutics committees to have a role in the CDS review
and deployment processes within existing institutional social systems using accepted organizational
processes. The direct benefits of this work will be an EDIT dashboard that can be used by oversight
committees to prioritize new and to revise deployed CDS, and infrastructure to close the loop of the learning
health system by transferring CDS revisions approved by oversight committee members into deployed CDS for
UGR. EDIT model implementation will be informed by mixed methods research strategies: Strategy 1, we will
conduct focus groups with oversight committee members in order to understand current roles, tasks and goals
of the committee, as well as to capture opinions about the best processes to prioritize, review and approve of
new and revised CDS for UGR as part of committee meeting activities. Research Strategy 2, we will conduct a
survey study with patients to assess preferences for the return of UGR with CDS and usability studies with
oversight committee members to gather feedback on the EDIT dashboard design. Strategy 3, we will conduct
time-motion observations of local oversight committee meetings prior to and after deploying the EDIT model in
order to plan a future, multi-institution, time-motion study with statistical power to detect differences between
oversight committees that use the EDIT dashboard and those that do not. The hypothesis is that time spent
prioritizing new and revised CDS will be shorter with use of the EDIT dashboard. Overall, the EDIT model
establishes processes that lower barriers to implementing robust genomic medicine programs that can be
followed by others. The Genomic Innovator Award will enable me to study, in team-science projects, how the
EDIT model can accelerate the institutional review and approval process of CDS for UGR. The broader impact
of this work is being able to study rate of UGR adoption by healthcare providers for deployed CDS for UGR.
项目概要
随着健康个体越来越多地获得基因组检测结果,表明他们患上贫困的风险
结果(例如疾病或药物不良反应),医疗保健提供者需要确保结果
通过解决结果的接收、工作流程挑战和责任问题来谨慎处理。
鉴于临床基因组测试可以在临床环境之外(例如,在研究中)启动,
从临床医生的角度来看,它们可以被描述为主动提供的基因组结果(UGR)。临床决策
支持 (CDS) 通过向临床医生提供建议,具有促进 UGR 采用的巨大潜力
以及在特定时间呈现的患者相关信息,以加强临床护理。为 UGR 部署 CDS
然而,在医疗保健环境中以可扩展的方式将取决于我们利用当地机构的能力
批准 CDS 指导和 UGR 战略的政策和监督结构。具体目标
该研究计划旨在开发和评估基于证据的决策支持实施
随着时间的推移 (EDIT) 模型,用于对 UGR 部署的 CDS 进行优先级排序和修改。 EDIT 模型将赋能
地方监督委员会(例如药剂学和治疗委员会)在 CDS 审查中发挥作用
和现有机构社会系统内使用公认的组织的部署过程
流程。这项工作的直接好处将是一个可供监督使用的编辑仪表板
委员会优先考虑新的和修改已部署的 CDS 以及基础设施以形成学习闭环
卫生系统,将监督委员会成员批准的 CDS 修订版转移到已部署的 CDS 中,以用于
UGR。编辑模型的实施将通过混合方法研究策略进行通知:策略 1,我们将
与监督委员会成员进行焦点小组讨论,以了解当前的角色、任务和目标
委员会的意见,并收集有关确定优先顺序、审查和批准的最佳流程的意见
新的和修订的 UGR CDS 作为委员会会议活动的一部分。研究策略2,我们将进行
对患者进行调查研究,以评估使用 CDS 恢复 UGR 的偏好以及使用 CDS 进行可用性研究
监督委员会成员收集有关编辑仪表板设计的反馈。策略3,我们将进行
在部署 EDIT 模型之前和之后对地方监督委员会会议的时间动态观察
为了计划未来的多机构时间运动研究,具有统计能力来检测之间的差异
使用和不使用 EDIT 仪表板的监督委员会。假设是花费的时间
使用 EDIT 仪表板,可以更短地确定新的和修订的 CDS 的优先级。总体而言,EDIT 模型
建立降低实施稳健基因组医学计划障碍的流程,这些计划可以
其次是其他人。基因组创新者奖将使我能够在团队科学项目中研究如何
EDIT模型可以加速UGR CDS的机构审查和批准过程。更广泛的影响
这项工作的重点是能够研究医疗保健提供者对 UGR 部署 CDS 的 UGR 采用率。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Willingness to Share Wearable Device Data for Research Among Mechanical Turk Workers: Web-Based Survey Study.
- DOI:10.2196/19789
- 发表时间:2021-10-21
- 期刊:
- 影响因子:7.4
- 作者:Taylor CO;Flaks-Manov N;Ramesh S;Choe EK
- 通讯作者:Choe EK
Risk for Poor Post-Operative Quality of Life Among Wearable Use Subgroups in an All of Us Research Cohort
我们所有人研究队列中可穿戴设备亚组术后生活质量差的风险
- DOI:10.1142/9789811270611_0004
- 发表时间:2022
- 期刊:
- 影响因子:0
- 作者:Nidhi Soley;Shanshan Song;N. Flaks;Casey Overby Taylor
- 通讯作者:Casey Overby Taylor
Facilitating Genetics Aware Clinical Decision Support: Putting the eMERGE Infrastructure into Practice.
- DOI:10.1055/s-0041-1729981
- 发表时间:2021-07
- 期刊:
- 影响因子:0
- 作者:Taylor, Casey Overby;Rasmussen, Luke V;Rasmussen-Torvik, Laura J;Prows, Cynthia A;Dorr, David A;Samal, Lipika;Aronson, Samuel
- 通讯作者:Aronson, Samuel
Will the Doctor "See" You Now? The Development and Implementation of a Targeted Telemedicine System for Primary Care.
- DOI:10.1055/s-0043-1776038
- 发表时间:2023-07
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CASEY OVERBY TAYLOR其他文献
CASEY OVERBY TAYLOR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CASEY OVERBY TAYLOR', 18)}}的其他基金
Real-World Data Estimates of Racial Fairness with Pharmacogenomics-Guided Drug Policy
以药物基因组学为指导的药物政策对种族公平性的真实世界数据估计
- 批准号:
10797705 - 财政年份:2023
- 资助金额:
$ 48.14万 - 项目类别:
Clinical Decision Support for Unsolicited Genomic Results
主动提供的基因组结果的临床决策支持
- 批准号:
10318291 - 财政年份:2020
- 资助金额:
$ 48.14万 - 项目类别:
Clinical Decision Support for Unsolicited Genomic Results
主动提供的基因组结果的临床决策支持
- 批准号:
10436990 - 财政年份:2020
- 资助金额:
$ 48.14万 - 项目类别:
Clinical Decision Support for Unsolicited Genomic Results
主动提供的基因组结果的临床决策支持
- 批准号:
10251062 - 财政年份:2020
- 资助金额:
$ 48.14万 - 项目类别:
Clinical Decision Support for Unsolicited Genomic Results
主动提供的基因组结果的临床决策支持
- 批准号:
10606011 - 财政年份:2020
- 资助金额:
$ 48.14万 - 项目类别:
Electronic Health Record-linked Decision Support for Communicating Genomic Data t
与电子健康记录相关的决策支持,用于交流基因组数据
- 批准号:
8772968 - 财政年份:2014
- 资助金额:
$ 48.14万 - 项目类别:
Electronic Health Record-linked Decision Support for Communicating Genomic Data t
与电子健康记录相关的决策支持,用于交流基因组数据
- 批准号:
8930122 - 财政年份:2014
- 资助金额:
$ 48.14万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 48.14万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 48.14万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 48.14万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 48.14万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 48.14万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 48.14万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 48.14万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 48.14万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 48.14万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 48.14万 - 项目类别:
Research Grant














{{item.name}}会员




